🔥 Thermo Fisher: Sizzling Hot Expansion?

Cathie Wood's ARK funds get in on Coinbase action.


Hey Global Investor, here’s what you need to know before the US markets open.

Market Snapshot 📈

S&P 500 (Yesterday’s Close) 4,170.42 +45.76 (1.11%)

NASDAQ (Yesterday’s Close) 14,038.76 +180.92 (1.31%)

FTSE 100 (5 PM IST) 7,0170.12 +33.62 (0.48%)

NIFTY 50 (Today’s Close) 14,617.85 +36.40 (0.25%)

USDINR (5 PM IST) 74.44 (1 Year -3.67%)


🔥 Top Movers

HMI +18.93%
WRI +12.42%
BALY +8.56%

KLXE -28.08%
AVIR -15.70%
MAXN -15.60%


🔥 Thermo Fisher: Sizzling Hot Expansion?

Thermo Fisher Scientific (TMO) announced that it would acquire PPD Inc. (PPD), a clinical research services provider, for $17.4B, after two acquisitions in 2021 already. (Tweet This)

Background
Thermo Fisher Scientific, Inc. is the world’s largest manufacturer of scientific instruments, consumables, and chemicals, among others. The company was founded in 1956 and went public in 2014. Thermo Fisher caters to many clients in hospitals, clinical labs, biotech, and pharmaceutical companies. As of 2021, the company has made 59 acquisitions and operates a global workforce of 80K, with a market value of $194.3B.

Thermo Fisher has a solid track record of profitability and beating analyst estimates. The company brought in $32.22B in revenue last year, up 26% Y-o-Y. Analysts predict that the company will top estimates once again when it announces quarterly results.

The reason behind Thermo Fisher’s success is its ability to innovate and double down on expansion consistently. The company recently acquired two biotechnology companies Henogen, and Messa Biotech, for over $1B. By acquiring PPD, Thermo Fisher will strengthen its pharmaceutical arm.

What Happened
PPD specializes in the drug development process through preclinical consulting, designing, and conducting clinical trials. The company, which went public last year, oversaw the Covid-19 trial sites of Moderna Inc (MRNA). The acquisition will be completed this year and enable the company to offer new and improved services for customers while increasing efficiency and cutting costs in the drug development process.

While Thermo Fisher gets access to PPD’s drug development platforms, PPD is likely to acquire more contracts as the pandemic increases the need for crucial suppliers for drugmakers. The demand for Contract Research Organizations (CRO) has bounced back after clinical trials were disrupted due to the pandemic. The increase in private and government spendings to discover new treatments is yet another impetus for this acquisition.

Separately, Thermo Fisher will invest $600M to expand its bioprocessing production capabilities. The investment will double the current manufacturing capacity with 11 new sites in the US and create 1.5k more jobs.

All seems well for now, but moving too fast can catch the eye of the tiger hiding in the bushes since the regulatory bodies are always on the prowl. Even so, the investors seem to have green-lighted the deal already!

Market Reaction
TMO closed the day at $494.38, up 3.42%. PPD also ended the day in the green at $45.80, up 6.51%.

Company Snapshot 📈

TMO $494.38 +16.34 (+3.42%)

Analyst Ratings (23 Analysts) BUY 83%  HOLD 17%  SELL 0%

 


Newsworthy 📰

  • Cancelled?: Advocacy group urges Zuckerberg to cancel plans to launch Instagram for kids (FB +1.65%)
  • Crypto Stock: ARK buys $110 mln Coinbase shares, adding to positions (COIN -1.68%)
  • Deliveries: Walmart investing in GM’s Cruise self-driving car company (WMT +0.60, GM +0.22%)

 


Later Today 🕒

  • Before Markets Open: Morgan Stanley Earnings (MS)
  • Before Markets Open: Bank of New York Mellon Corp Earnings (BK)
  • 6:00 PM IST: Housing starts (SAAR)

Fun Fact of The Day 🌞

Glaciers and ice sheets hold about 69% of the world’s freshwater


Disclaimer: The content of this article has been created and published by Winvesta India Technologies Pvt. Ltd., in order to ease the reader’s understanding of the subject matter. The information and/or content (collectively “Information”) provided herein is general information sourced through various news reports and does not constitute a research report or a research analysis. The Information is not intended to offer advice, target or solicit any particular customer or group of customers to buy or sell securities. 

Winvesta does not render any research or advisory services and provides a more detailed description of its services on its website and mobile application along with the terms and conditions published therein from time to time. While reasonable care has been exercised to ensure that the Information is adequate and reliable, no representation is made by Winvesta as to its accuracy or completeness and Winvesta, its affiliates, subsidiaries and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this Information. Neither Winvesta nor any of its affiliates are acting as an investment adviser, research analyst or in any other fiduciary capacity. Accordingly, reader’s are expected to undertake their own due diligence in consultation with their own advisors and are advised not to solely rely on the Information. Any such reliance shall be at the reader’s own risk. 

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing.


Start Building Your Global Portfolio Today

Download Winvesta App now to Get Started